SETASTINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H28ClNO
Molecular Weight	357.917
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(OCCN1CCCCCC1)(C2=CC=CC=C2)C3=CC=C(Cl)C=C3

InChI

InChIKey=VBSPHZOBAOWFCL-UHFFFAOYSA-N

InChI=1S/C22H28ClNO/c1-22(19-9-5-4-6-10-19,20-11-13-21(23)14-12-20)25-18-17-24-15-7-2-3-8-16-24/h4-6,9-14H,2-3,7-8,15-18H2,1H3

HIDE SMILES / InChI

Molecular Formula	C22H28ClNO
Molecular Weight	357.917
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982751 | https://www.drugs.com/international/setastine.html

Setastine (Loderix) is a potent antagonist of histamine H1-receptor mediated responses. Setastine inhibits anaphylactic shock in guinea-pigs sensitized by horse serum. No antiserotonin, anticholinergic and antiadrenergic effect of the compound can be detected. Setastine has a long lasting (up to 16 h) antihistamine effect with a good oral effectiveness. It shows no cardiovascular effects in cats. Setastine shows a much weaker CNS depressant activity than clemestine fumarate. In displacement studies (3H-mepyramine) setastine had significantly weaker affinity for the central nervous system (CNS) H1-receptors than clemastine fumarate. It is concluded that setastine is a non-sedative highly active H1-antagonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL3573 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1982751	Antagonist 2778

PubMed

Title	Date	PubMed
Results obtained with Loderix tablet in chronic rhinitis patients.	1989	2576575
Pharmacology of the new H1-receptor antagonist setastine hydrochloride.	1990 Dec	1982751
Comparative clinical examination of Loderix (setastinum) and astemizole in pollenosis.	1993	8029782
[Observation on therapeutic effect of acupoint injection desensitization with autoblood on chronic urticaria].	2011 Jul	21823283

Patents

Sample Use Guides

In Vivo Use Guide

For prolonged use a dose of 2 mg three times/day (t.i.d.) is recommended. The antihistaminic effect of setastine almost equalled that of clemastine given in a dose of 1 mg t.i.d.

Route of Administration: Oral

In Vitro Use Guide

At low concentrations Setastine (Loderix) preincubated with rat peritoneal mast cells for 10 min prior to the addition of various stimulants (immune aggregates, ionophore A23187 and compound 48/80) produced a concentration-dependent inhibition of histamine release, while at high concentrations it induced the release of histamine. The IC50 values were calculated as 0.2, 15 and 50 uM by using immune aggregate, (rat IgG2 alpha + anti rat IgG) calcium ionophore and 48/80 as stimulants, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:27:31 GMT 2023` Edited by `admin` on `Fri Dec 15 16:27:31 GMT 2023`
Record UNII	6G3OCF528J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SETASTINE

Official Name

English

SETASTINE [MI]

Common Name

English

setastine [INN]

Common Name

English

Setastine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29578